With the latest development, Kazakhstan became the first nation outside Russia to grant authorisation to Sputnik M.
The Gamaleya Center in Russia developed the vaccine specifically for use in adolescents.
A two-dose vaccine, Sputnik M is based on a safe human adenoviral vectors platform that has been extensively studied for more than three decades.
As against the Sputnik V vaccine, Sputnik M has five times reduced concentration of viral particles for each dose.
In November last year, the Russian Ministry of Health registered the Sputnik M vaccine based on results from clinical trials that established the favourable safety and immunogenicity profile of the vaccine in adolescents.
Following inoculation with Sputnik M, no serious adverse events were reported in the trials.
The latest findings are consistent with results obtained during the trials and real-world data on administering adults with Sputnik V.
Currently authorised in 71 countries, Sputnik V elicits a robust and durable immune response against Covid-19 compared to various other vaccines.
According to a comparative study carried out at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy, Sputnik V was found to offer over two times increased virus neutralising antibody titers against Omicron variant versus two-dose regimen with Pfizer’s Covid-19 vaccine.
Data from various studies showed that Sputnik V offers a robust immune response against the Omicron variant of the SARS-CoV-2 virus.
This response can be further enhanced by boosting with one dose Sputnik Light vaccine.
Earlier this month, the Drug Controller General of India granted authorisation to Sputnik Light against Covid-19.